Analytical Data
-
Gene name
BMPRIB/ALK-6
- Application
-
Alternative Names
Bone morphogenetic protein receptor type-1B; BMPR-1B; CDw293
-
Species
Human
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O00238
-
Expression Region
K14-R126
-
Protein Length
Extracellular Domain
-
Molecular Weight
110 kDa.
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BMPRIB, also known as Activin-like kinase 6 (ALK-6), is a member of the bone morphogenetic protein (BMP) receptor family, playing a crucial role in various biological processes, including development, differentiation, and tissue homeostasis. Research into BMPRIB/ALK-6 has gained significant attention due to its involvement in the BMP signaling pathway, which is vital for the regulation of cellular activities and organogenesis. Dysregulation of this pathway has been implicated in several diseases, including cancer and skeletal disorders, making BMPRIB a potential therapeutic target. Studies have shown that BMPRIB/ALK-6 is crucial for mesenchymal stem cell differentiation into various lineages, particularly osteoblasts and chondrocytes, indicating its importance in bone and cartilage formation. Additionally, BMPRIB/ALK-6 and its ligands have been explored in the context of tissue repair and regeneration, emphasizing their potential in regenerative medicine. Advances in recombinant protein technology have enabled researchers to produce and characterize BMPRIB/ALK-6, facilitating detailed studies of its structure, function, and interactions with different signaling molecules. Understanding the precise mechanisms of BMPRIB/ALK-6 in cellular signaling and its role in disease conditions can pave the way for innovative therapeutic approaches that harness BMP signaling for tissue engineering and regenerative therapies. As a result, continued investigation into the biology and applications of BMPRIB/ALK-6 is likely to provide valuable insights into its potential as a target for drug development and tissue regeneration strategies.
